EP2718722A1 - Procédé de détection de diagnostic à base de protéomique d'une sinusite chronique - Google Patents

Procédé de détection de diagnostic à base de protéomique d'une sinusite chronique

Info

Publication number
EP2718722A1
EP2718722A1 EP12726000.8A EP12726000A EP2718722A1 EP 2718722 A1 EP2718722 A1 EP 2718722A1 EP 12726000 A EP12726000 A EP 12726000A EP 2718722 A1 EP2718722 A1 EP 2718722A1
Authority
EP
European Patent Office
Prior art keywords
subject
respiratory tract
upper respiratory
nthi
protein profile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12726000.8A
Other languages
German (de)
English (en)
Other versions
EP2718722B1 (fr
Inventor
Subinoy DAS
Lauren O. Bakaletz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University
Nationwide Childrens Hospital Inc
Original Assignee
Ohio State University
Nationwide Childrens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University, Nationwide Childrens Hospital Inc filed Critical Ohio State University
Priority to PL12726000T priority Critical patent/PL2718722T3/pl
Publication of EP2718722A1 publication Critical patent/EP2718722A1/fr
Application granted granted Critical
Publication of EP2718722B1 publication Critical patent/EP2718722B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/285—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/14—Disorders of ear, nose or throat

Definitions

  • the invention provides for a proteomic approach for identification of specific bacterial protein profiles that may be used in the development of methods for the diagnosis of bacterial chronic sinusitis.
  • the invention provides for methods of determining the presence for pathogenic bacteria in the upper respiratory tract of a subject using protein profiles of the pathogenic bacteria.
  • the invention also provides for methods of diagnosing a bacterial infection of the upper respiratory tract of a subject using protein profiles of the pathogenic bacteria.
  • the invention provides for devices, immunoassays and kits for identifying pathogenic bacteria in the upper respiratory tract.
  • Otitis media, sinusitis, bronchitis, pharyngitis, and nonspecific upper respiratory tract infections (URTI) account for approximately 75% of outpatient antibiotic prescriptions in the United States. Antibiotic use remains high despite the fact that greater than 85% of these infections are due to viruses and resolve without complication. Nonetheless, those remaining infections that are indeed due to bacterial pathogens require more effective management than is currently available. Bacterial cultures provide limited diagnostic value because the most common bacteria responsible for URTI are also often commensal organisms in the nasopharynx.
  • Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis While viral infections are often self-limiting, therapeutic delay of bacterial disease can lead to complications, permanent sequelae and severe morbidity and mortality.
  • Diagnosis is mainly based on clinical manifestations. Signs and symptoms of disease of bacterial and nonbacterial etiologies are often indistinguishable. Specific bacterial identification by traditional microbiological culture techniques often fail to detect microorganisms growing within biofilms. Contamination of specimens by resident colonizing flora often results in laboratory culture reports of uncertain clinical value.
  • bacterial biofilms produce a distinct set of proteins may be used to distinguish between commensal and pathogenic states.
  • the invention provides for methods of identifying the protein profile of bacterial biofilms. The methodology involves detecting trace quantities of signature proteins that identify specific bacterial pathogens from typically sterile sites in the paranasal sinus cavities.
  • biofilms produced by nontypeable Haemophilus influenzae (NTHI ) over 10 days generate a specific protein profile.
  • Biofilms formed by NTHI in vitro release a signature set of proteins into their environment that remains identifiable for several days.
  • Outer membrane proteins (OMPs) are predominant components of the NTHI biofilm supernatant.
  • OMP P5 outer membrane protein P5
  • OMP P2 outer membrane protein P2
  • Additional OMPs include high molecular weight adhesin 1/high molecular weight adhesin 2 (HMW1/HMW2), and IgA-protease.
  • HMW1/HMW2 OMP P5 are mediators of adhesion to epithelial cells
  • OMP P2 is a porin and IgA protease functions to cleave host IgA.
  • NTHI was used as an example for the study but the same methods may be used to identify the presence of any pathogenic bacteria including those known to cause chronic sinusitis such as Haemophilus influenza, Streptococcus pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
  • the invention also provides for an immunoassay device that involves obtaining a sample of the secretions within the typically sterile paranasal sinus cavities, and rapidly detecting the presence of trace quantities of signature proteins that identify specific bacterial pathogens from these typically sterile sites.
  • the invention provides for methods of detecting the presence of a pathogenic bacteria in the upper respiratory tract of a subject comprising the steps of: a) obtaining a sample of secretions from the upper respiratory tract of the subject; b) generating a protein profile of the sample; c) comparing the protein profile with a reference protein profile, wherein the reference protein profile identifies a pathogenic bacteria; and d) determining whether the protein profile of the sample associates to the reference protein profile, wherein association is indicative of the presence of the pathogenic bacteria in the upper respiratory tract of the subject.
  • the invention also provides for methods of detecting the presence of a pathogenic bacteria in the upper respiratory tract of a subject as described above wherein the method further comprises the step of administering a therapeutic compound to reduce or eliminate the pathogenic bacteria in the upper respiratory tract of the subject.
  • exemplary therapeutic compounds that reduce or eliminate pathogenic bacteria in the upper respiratory tract include antibiotics such as penicillin, erythromycin, amoxicillin, thimethoprim-sulfamethoxazole, doxycyline, cefpodoxime, cefuroxime, cefdinir, clarithromycin, azithromycin, levofloxacin, gatifloxacin, and moxifloxacin, alpha- adreneric agonists such as oxymetazoline
  • anticholinergic agents such as ipratropium bromide
  • antihistamines such as chlorpheniramine maleate, beta-agonist bronchodilators, non-steroidal anti-inflammatory drugs, camphor, menthol, Echinacea, mast cell stabilizers such as cromolyn sodium
  • topical nasal steroids such as fluticasone propionate and zinc salts.
  • the invention also provides for methods of detecting the presence of a pathogenic bacteria in the upper respiratory tract of a subject as described above wherein the method further comprises the step of informing the subject of the presence or absence of the pathogenic bacteria in the upper respiratory tract.
  • the invention also provides for methods of detecting the presence of a pathogenic bacteria in the upper respiratory tract of a subject as described above wherein the method further comprises the step of diagnosing the subject with a bacterial infection, wherein the presence of the pathogenic bacteria in the upper respiratory tract of the subject is indicative of a bacterial infection.
  • pathogenic bacteria refers to any disease causing bacteria.
  • mensal bacteria refers to harmless or non-disease causing bacteria.
  • the methods of the invention also may be used to distinguish the presence of commensal bacteria verses pathogenic bacteria in the upper respiratory tract of a subject.
  • the invention also provides for methods of diagnosing a bacterial infection in the upper respiratory tract of a subject comprising the steps of: a) obtaining a sample of secretions from the upper respiratory tract of the subject; b) generating a protein profile of the sample; c) comparing the protein profile of the sample with a reference protein profile, wherein the reference protein profile indentifies a pathogenic bacteria; and d) determining whether the protein profile of the sample associates to the protein profile; wherein association is indicative of a bacterial infection in the upper respiratory tract of the subject.
  • the invention also provides for methods of diagnosing a bacterial infection in the upper respiratory tract of a subject as described above wherein the method further comprises the step of the step of informing the subject of the diagnosis of a bacterial infection in the upper respiratory tract.
  • the invention also provides for methods of diagnosing a bacterial infection in the upper respiratory tract of a subject as described above wherein the method further comprises the step of administering a therapeutic compound to treat the bacterial infection.
  • a treatment for a bacterial infection will reduce or alleviate the symptoms caused by the pathogenic bacteria or eliminate the bacteria from the site of infection.
  • Exemplary therapeutic compounds that treat a bacterial infection in the upper respiratory tract include antibiotics such as penicillin, erythromycin, amoxicillin, thimethoprim- sulfamethoxazole, doxycyline, cefpodoxime, cefuroxime, cefdinir, clarithromycin, azithromycin, levofloxacin, gatifloxacin, and moxifloxacin, alpha- adreneric agonists such as oxymetazoline hydrochloride, anticholinergic (parasympatholytic) agents such as ipratropium bromide, antihistamines such as chlorpheniramine maleate, beta- agonist bronchodilators, non-steroidal anti-inflammatory drugs, camphor, menthol, Echinacea, mast cell stabilizers such as cromolyn sodium, topical nasal steroids such as fluticasone propionate, budenoside, mometasone, triamcinolone, and dex
  • protein profile refers to at least one protein that is at least partially identified or characterized so that the presence or absence of the protein in any particular sample may be monitored.
  • reference protein profile refers to a protein profile generated for a known control or standard sample.
  • a protein profile of a sample associates with a reference protein profile when one or more the proteins in the reference profile are present in the sample profile at a
  • the profiles are scored to predict how likely the mass of a fragment that it detected is likely from the peptide sequence it is predicted it to be, and how much quantity of the peptide there is in the supernatant.
  • Mascot Mass spectrometry data analysis
  • a statistical evaluation of matches between observed and projected peptide fragments rather than cross correlation may be used to determine in the sample associates with a reference protein profile. See, e.g., Electrophoresis, 20(18) 3551-67 (1999).
  • the preceding methods may be carried out for any pathogenic bacteria which infects the upper respiratory tract, including Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa or Stenotrophomonas maltophilia.
  • pathogenic bacteria including Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa or Stenotrophomonas maltophilia.
  • the invention also provides for uses of a therapeutic compound for the preparation of a medicament to reduce or eliminate the pathogenic bacteria in the upper respiratory tract of a subject or uses to treat a bacterial infection in the upper respiratory tract of a subject, wherein the subject has a protein profile that associates to a reference protein profile, and wherein the association is indicative of the presence of the pathogenic bacteria or bacterial infection in the upper respiratory tract of the subject as determined by any of the preceding methods of detecting the presence of a pathogenic bacteria or diagnosing a bacterial infection in the upper respiratory tract of a subject.
  • the invention also provides for therapeutic compositions for the reduction or elimination of a pathogenic bacteria in the upper respiratory tract of a subject or for the treatment of a bacterial infection in the upper respiratory tract of a subject, wherein the subject has a protein profile that associates to a reference protein profile, and wherein the association is indicative of the presence of the pathogenic bacteria or bacterial infection in the upper respiratory tract of the subject tract of the subject as determined by any of the preceding methods of detecting the presence of a pathogenic bacteria or diagnosing a bacterial infection in the upper respiratory tract of a subject.
  • Exemplary therapeutic compounds that treat a bacterial infection in the upper respiratory tract include antibiotics such as penicillin, erythromycin, amoxicillin,
  • alpha-adreneric agonists such as oxymetazoline hydrochloride, anticholinergic (parasympatholytic) agents such as ipratropium bromide, antihistamines such as chlorpheniramine maleate, beta-agonist bronchodilators, non-steroidal anti-inflammatory drugs, camphor, menthol, Echinacea, mast cell stabilizers such as cromolyn sodium, topical nasal steroids such as fluticasone propionate, budenoside, mometasone, triamcinolone, and dexamethasone, and zinc salts.
  • alpha-adreneric agonists such as oxymetazoline hydrochloride, anticholinergic (parasympatholytic) agents such as ipratropium bromide, antihistamines such as chlorpheniramine maleate, beta-agonist bronchodilators, non-steroidal anti-inflammatory drugs, camphor, menthol, Echinacea, mast cell stabilizer
  • the invention provides for methods of detecting the presence of Nontypeable Haemophilus influenzae (NTHI ) bacteria in the upper respiratory tract of a subject comprising the steps of: a) obtaining a sample from the upper respiratory tract of the subject; b) detecting the presence of at least one biomarker in the sample, wherein the biomarkers are selected from the group consisting of: HMW1/HMW2, OMP P5 , OMP P2 and IgA -protease, and wherein the presence of at least one biomarker indicates the presence of NTHI bacteria in the upper respiratory tract of the subject.
  • the method comprises detecting the presence of OMP P2 and/or OMP P5 in the sample, wherein the presence of OMP P2 and/or OMP P5 indicates the presence of NTHI bacteria in the upper respiratory tract of the subject.
  • the invention also provides for methods of detecting the presence of NTHI bacteria in the upper respiratory tract of a subject wherein the method further comprises the step of administering a therapeutic compound to reduce or eliminate the NTHI bacteria in the upper respiratory tract of the subject.
  • exemplary the-apeutic compounds that reduce or eliminate the NTHI bacteria in the upper respiratory tract include antibiotics such as penicillin, erythromycin, amoxicillin, thimethoprim- sulfamethoxazole, doxycyline, cefpodoxime, cefuroxime, cefdinir, clarithromycin, azithromycin, levofloxacin, gatifloxacin, and moxifloxacin, alpha-adreneric agonists such as oxymetazoline hydrochloride, anticholinergic (parasympatholytic) agents such as ipratropium bromide, antihistamines such as
  • chlorpheniramine maleate beta-agonist bronchodilators
  • non-steroidal anti-inflammatory drugs camphor, menthol, Echinacea
  • mast cell stabilizers such as cromolyn sodium
  • topical nasal steroids such as fluticasone propionate, budenoside, mometasone, triamcinolone, and dexamethasone, and zinc salts.
  • the invention also provides for methods of diagnosing a NTHI infection in the upper respiratory tract of a subject comprising the steps of: a) obtaining a sample of secretions from the upper respiratory tract of the subject, b) detecting the presence of at least one biomarker in the sample, wherein the biomarkers are selected from the group consisting of: HMW1/HMW2, OMP P5, OMP P2 and IgA-protease, and wherein the presence of at least one biomarkers indicates an NTHI infection in the upper respiratory tract of the subject.
  • the method comprises detecting the presence of OMP P2 and/or OMP P5 in the sample, wherein the presence of OMP P2 and/or OMP P5 indicates a NTHI bacterial infection in the upper respiratory tract of the subject.
  • the invention also provides for methods of diagnosing a NTHI infection in the upper respiratory tract of a subject as described above wherein the method further comprises the step of informing the subject of the diagnosis of a NTHI infection in the upper respiratory tract.
  • the invention also provides for methods of diagnosing NTHI infection in the upper respiratory tract of a subject as described above wherein the method further comprises the step of administering a therapeutic compound to treat the NTHI infection in the upper respiratory tract of the subject.
  • a treatment for a NTHI infection will reduce or alleviate the symptoms caused by the NTHI bacteria or eliminate the NTHI bacteria from the site of infection.
  • Exemplary therapeutic compounds that treat a NTHI infection in the upper respiratory tract include antibiotics such as penicillin, erythromycin, amoxicillin,
  • alpha-adreneric agonists such as oxymetazoline hydrochloride, anticholinergic (parasympatholytic) agents such as ipratropium bromide, antihistamines such as chlorpheniramine maleate, beta-agonist bronchodilators, non- steroidal anti-inflammatory drugs, camphor, menthol, Echinacea, mast cell stabilizers such as cromolyn sodium, topical nasal steroids such as fluticasone
  • propionate propionate, budenoside, mometasone, triamcinolone, and dexamethasone, and zinc salts.
  • upper respiratory tract includes the nose or nostrils, nasal cavity, mouth, throat (pharynx), paranasal sinus cavity and voice box (larynx).
  • the respiratory system is lined with a mucous membrane that secretes mucus or fluid. This secreted mucus and fluid is referred to herein as "secretions.”
  • secretions may be collected from the paranasal sinus cavity including the middle meatus or the ethmoid infundibulum.
  • the "paranasal sinus cavity” refers to the frontal sinuses (in the forehead), maxillary sinuses (behind the cheek bones), ethmoid sinuses (between the eyes) and the sphenoid sinuses (behind the eyes).
  • the invention also provides for use of a therapeutic compound for the preparation of a medicament to reduce or eliminate NTHI bacteria in the upper respiratory tract of a subject or to treat a NTHi infection in the upper respiratory tract of a subject, wherein the presence of NTHI bacteria or a NTHI infection is determined by the presence of at least one biomarker selected from OMP P2 and OMP P5 as determined by any of the preceding methods of detecting the presence of a NTHI bacterial or diagnosing a NTHI infection in the upper respiratory tract of a subject method as determined by the preceding methods of detecting the presence of NTHI bacteria or diagnosing a NTHI infection in the upper respiratory tract of a subject.
  • the invention also provides for a therapeutic composition for the reduction or elimination of NTHI bacteria or for the treatment of NTHI infection in the upper respiratory tract of a subject, wherein the presence of NTHi bacteria or NTHI infection as determined by any of the preceding methods of detecting the presence of a NTHI bacterial or diagnosing a NTHI infection in the upper respiratory tract of a subject.
  • any of the preceding methods, uses or therapeutic compositions may be carried out on a subject suffering from chronic sinusitis, or a subject that is prone to suffering from recurrent acute sinusitis.
  • any of the preceding methods may be carried out on a subject suffering from Otitis media, bronchitis, pharyngitis, and nonspecific upper respiratory tract infections.
  • the invention also provides for methods, uses or therapeutic compositions for treating chronic sinusitis or a pathogenic bacterial infection of the upper respiratory tract in a subject comprising detecting a pathogenic bacteria in the upper respiratory tract of the subject using any of the preceding methods and administering the appropriate dose of a therapeutic compound known to effectively treat the particular pathogenic bacteria detected within the upper respiratory tract of the subject.
  • a treatment for a chronic sinusitis or a pathogenic bacterial infection will reduce or alleviate the symptoms caused by the pathogenic bacteria or eliminate the pathogenic bacteria from the site of the infection.
  • Exemplary therapeutic compounds include antibiotics such as penicillin, erythromycin, amoxicillin, thimethoprim- sulfamethoxazole, doxycyline, cefpodoxime, cefuroxime, cefdinir, clarithromycin, azithromycin, levofloxacin, gatifloxacin, and moxifloxacin, alpha- adreneric agonists such as oxymetazoline hydrochloride, anticholinergic (parasympatholytic) agents such as ipratropium bromide, antihistamines such as chlorpheniramine maleate, beta-agonist bronchodilators, non-steroidal anti-inflammatory drugs, camphor, menthol, Echinacea, mast cell stabilizers such as cromolyn sodium, topical nasal steroids such as fluticasone propionate, budenoside, mometasone, triamcinolone, and dexamethasone, and zinc salts.
  • the invention also provides for methods of treating, uses and therapeutic compositions for chronic sinusitis or a pathogenic bacterial infection of the upper respiratory tract in a subject comprising diagnosing a pathogenic bacteria infection in the upper respiratory tract of the subject using any of the preceding methods and administering the appropriate dose of a therapeutic compound known to effectively treat the particular pathogenic bacteria detected within the upper respiratory tract of the subject.
  • Exemplary therapeutic compounds include antibiotics such as penicillin, erythromycin, amoxicillin, thimethoprim- sulfamethoxazole, doxycyline, cefpodoxime, cefuroxime, cefdinir, clarithromycin, azithromycin, levofloxacin, gatifloxacin, and moxifloxacin, alpha-adreneric agonists such as oxymetazoline hydrochloride, anticholinergic (parasympatholytic) agents such as ipratropium bromide, antihistamines such as chlorpheniramine maleate, beta-agonist bronchodilators, non-steroidal anti-inflammatory drugs, camphor, menthol, Echinacea, mast cell stabilizers such as cromolyn sodium, topical nasal steroids such as fluticasone
  • antibiotics such as penicillin, erythromycin, amoxicillin, thimethoprim- sulfamethoxazole, d
  • the sample may be collected using sterile swabs, sterile gauze, nasal washing, suction tube or a balloon catheter.
  • the biomarker may be detected using a monoclonal antibody.
  • an immunoassay may be used to detect the biomarker of interest in any of the preceding methods of the invention.
  • the sample may be collected with a device comprising a substrate presenting antibodies specific for the biomarkers of interest, such as a balloon catheter wherein the substrate is threaded into the suction port of the catheter.
  • An another aspect of the invention provides for immunoassays for detecting the presence of a pathogenic bacteria in the upper respiratory tract of a subject comprising the steps of a) obtaining a sample of secretions from the upper respiratory tract of the subject using a device comprising antibodies specific for at least one biomarker associated with the presence of a pathogenic bacteria in the upper respiratory tract of the subject; b) detecting the presence of at least one biomarker associated with the presence of a pathogenic bacteria in the upper respiratory tract of the subject to generate a protein profile; c) comparing the protein profile with a reference protein profile, wherein the reference protein profile identifies a pathogenic bacteria; and d) determining whether the protein profile of the sample associates to the reference protein profile, wherein association is indicative of the presence of the pathogenic bacteria in the upper respiratory tract of the subject.
  • immunoassay is a laboratory approach to directly or indirectly detect protein or peptide in fluid, e.g. biological fluid, by use of an immunological reaction between an antigen and an antibody.
  • antibody is synonymous with “immunoglobulin,” and includes naturally occurring human antibodies, polyclonal antibodies, and monoclonal antibodies.
  • antibody is meant to include both the native antibody and biologically active and synthetic derivatives of antibodies, such as, for example, Fab', F(ab")2 or Fv as well as single-domain and single-chain antibodies.
  • a biologically active derivative of an antibody retains the ability to bind an antigen.
  • the invention provides for methods and immunoassays that use antibodies specific for the biomarkers of interests, such as monoclonal antibodies that specifically bind biomarkers of interest, e.g. OMP P2 and OMP P5.
  • the immunoassays described above may further comprising a step of diagnosing the subject with a bacterial infection wherein the presence of the pathogenic bacteria in the upper respiratory tract of the subject is indicative of a bacterial infection.
  • the invention also provides for any of the preceding immunoassay further comprising the step of administering a therapeutic compound in an amount effective to treat the bacterial infection.
  • Exemplary therapeutic compounds include antibiotics such as penicillin, erythromycin, amoxicillin, thimethoprim-sulfamethoxazole, doxycyline, cefpodoxime, cefuroxime, cefdinir, clarithromycin, azithromycin, levofloxacin, gatifloxacin, and moxifloxacin, alpha- adreneric agonists such as oxymetazoline hydrochloride, anticholinergic (parasympatholytic) agents such as ipratropium bromide, antihistamines such as chlorpheniramine maleate, beta-agonist bronchodilators, non-steroidal anti-inflammatory drugs, camphor, menthol, Echinacea, mast cell stabilizers such as cromolyn sodium, topical nasal steroids such as fluticasone propionate, budenoside, mometasone, triamcinolone, and dexamethasone, and zinc salts.
  • antibiotics
  • the pathogenic bacteria detected may be any of the preceding immunoassays.
  • the invention also provides for uses of a therapeutic compound for the preparation of a medicament to reduce or eliminate NTHI bacteria in the upper respiratory tract of a subject or to treat a NTHi infection in the upper respiratory tract of a subject, wherein the presence of NTHi bacterial or a NTHi infection is determined by the presence of at least one biomarker selected from OMP P2 and OMP P5 as determined by any of the preceding
  • the invention provides for a therapeutic composition for the reduction or elimination of NTHI bacteria in the upper respiratory tract of a subject or for the treatment of NTHI infection in the upper airway of a subject, wherein the presence of NTHi bacteria or NTHI infection is determined by the presence of at least one biomarker selected from OMP P2 and OMP P5 as determined by any of the preceding immunoassays.
  • the invention provides for immunoassays for detecting the presence of a nontypeable NTHI bacteria in the upper respiratory tract of a subject comprising the steps of a) obtaining a sample of secretions from the upper respiratory tract of the subject using a device comprising antibodies specific for at least one biomarker associated with the presence of a NTHI bacteria in the upper respiratory tract of the subject, wherein at least one biomarker is OMP P2 or OMP P5; b) detecting the presence of at least one biomarker associated with the presence of a NTHI bacteria in the upper respiratory tract of the subject to generate a protein profile; c) comparing the protein profile with a reference protein profile, wherein the reference protein "-ofile identifies NTHI bacteria; and d) determining whether the protein profile of the sample associates to the reference protein profile, wherein association is indicative of the presence of the NTHI bacteria in the upper respiratory tract of the subject.
  • the invention also provides for immunoassays for detecting the presence NTHI bacteria in the upper respiratory tract of a subject as described above further comprising a step of diagnosing the subject with a NTHI infection wherein the presence of NTHI bacteria in the upper respiratory tract of the subject is indicative of a NTHI infection.
  • the invention also provides for any of the preceding immunoassays, which further comprise the step of administering a therapeutic compound in an amount effective to treat the bacterial infection.
  • exemplary therapeutic compounds include antibiotics such as penicillin, erythromycin, amoxicillin, thimethoprim- sulfamethoxazole, doxycyline, cefpodoxime, cefuroxime, cefdinir, clarithromycin, azithromycin, levofloxacin, gatifloxacin, and moxifloxacin, alpha-adreneric agonists such as oxymetazoline hydrochloride, anticholinergic (parasympatholytic) agents such as ipratropium bromide, antihistamines such as
  • chlorpheniramine maleate beta-agonist bronchodilators
  • non-steroidal anti-inflammatory drugs camphor, menthol, Echinacea
  • mast cell stabilizers such as cromolyn sodium
  • topical nasal steroids such as fluticasone propionate, budenoside, mometasone, triamcinolone, and dexamethasone, and zinc salts.
  • the invention provides for immunoassays for diagnosing a NTHI infection in the upper respiratory tract of a subject comprising the steps of a) obtaining a sample of secretions from the upper respiratory tract of the subject using a device comprising antibodies specific for at least one biomarker associated with the presence of a NTHI in the upper respiratory tract of the subject, wherein the at least one biomarker is OMP P2 or OMP P5; b) detecting the presence of at least one biomarker associated with the presence of a NTHI in the upper respiratory tract of the subject to generate a protein profile; c) comparing the protein profile with a reference protein profile, wherein the reference protein profile identifies NTHI; and d) determining whether the protein profile of the sample associates to the reference protein profile, wherein association is indicative of a NTHI infection in the upper respiratory tract of the subject.
  • the invention also provides for any of the preceding immunoassays further comprising the step of informing the subject of the presence of a NTHI bacteria or a NTHI infection in the upper respiratory tract of the subject.
  • exemplary therapeutic compounds include antibiotics such as penicillin, erythror ⁇ vcin, amoxicillin, thimethoprim- sulfamethoxazole, doxycyline, cefpodoxime, cefuroxime, cefdinir, clarithromycin, azithromycin, levofloxacin, gatifloxacin, and moxifloxacin, alpha- adreneric agonists such as oxymetazoline hydrochloride, anticholinergic (parasympatholytic) agents such as ipratropium bromide, antihistamines such as chlorpheniramine maleate, beta-agonist bronchodilators, non-steroidal anti-inflammatory drugs, camphor, menthol, Echinacea, mast cell stabilizers
  • sample used in any of the preceding immunoassays may be obtained using a sterile swab, sterile gauze, suction tube or a balloon catheter.
  • the invention provides for a device for obtaining a sample of secretions from the upper respiratory tract of a subject comprising a substrate presenting antibodies specific for at least one biomarker associated with the presence of a pathogenic bacteria in the upper respiratory tract of the subject.
  • the invention also provides for devices for carrying out any of the preceding methods of the invention or any of the preceding immunoassays of the invention which is used for obtaining a sample of secretions from the upper respiratory tract of a subject comprising a substrate presenting antibodies specific for biomarkers associated with the presence of a pathogenic bacteria in the upper respiratory tract of the subject.
  • the antibodies may be specific for OMP P2 or OMP P5, such as monoclonal antibodies that specifically bind NTHI OMP P2 or monoclonal antibodies that specifically bind NTHI OMP P5.
  • kits for carrying out any of the preceding methods or immunoassys.
  • the kits comprise a substrate presenting antibodies specific for at least one biomarker associated with the presence of a pathogenic bacteria or a bacterial infection in the upper respiratory tract of the subject.
  • the kits comprise devices for obtaining the sample from the sterile compartments within the upper respiratory tract of the subject and generating a protein profile associated with a pathogenic bacteria or bacterial infection in the upper respiratory tract of the subject.
  • the kits may also comprise antibodies that specifically bind the protein biomarkers of interest and components for immunoassays to detect the protein biomarkers using these antibodies.
  • Figure 1 depicts a silver stain of the distinct protein profile maintained over time in the NTHI biofilm supernatant.
  • Figure 2 depicts a Western blot analysis verifying the presence of the NTHI OMPs in NTHI biofilm supernatant.
  • Figure 3 depicts a Western blot analysis verifying the presence of OMP P2 and OMP P5 in the biofilm supernatant of various strains of NTHI.
  • the invention provides for methods with improved sensitivity and specificity for detecting and diagnosing bacterial sinusitis.
  • the methods of invention comprise antibody-based bacterial detection of proteins within secretions of pathogenic biofilm located within the paranasal sinus cavities. These methods allow for the detection of trace quantities of signature proteins that identify specific bacterial pathogens from typically sterile sites in the paranasal sinus cavities.
  • the methods of the invention provide for the ability to avoid broad- spectrum, empiric antibiotics which are often inappropriately given treat upper viral respiratory infections due to the difficulty in diagnosing bacterial sinusitis with a high sensitivity and high specificity.
  • the methods of the invention are an improvement over typical bacterial cultures because these cultures have very low sensitivity for detecting bacterial biofilms and low specificity for distinguishing between commensal and pathogenic organisms.
  • the invention also provides for a device that involves delivering a wire through a balloon catheter to the typically sterile paranasal sinus cavities, sampling mucus from these sites, and rapidly detecting the presence of trace quantities of signature proteins that identify specific bacterial pathogens from these typically sterile sites.
  • an immunoassay may be run to generate a protein profile that is compared to a reference protein profile generated for the pathogenic bacteria known to cause chronic sinusitis or an infection of the upper respiratory tract.
  • biomarker refers to a naturally occurring molecule, gene, or characteristic by which a particular pathological or physiological process, disease, or the like can be identified or characterized.
  • biomarker may refer to a protein measured in sample whose concentration reflects the severity or presence of some disease state.
  • Biomarkers may be measured to identify risk for, diagnosis of or progression of a
  • biomarkers include proteins, hormones, prohormones, lipids, carbohydrates, DNA, RNA and combinations thereof.
  • biomarkers for NTHI pathogenic bacteria include outer membrane protein P2 (OMP P2: SEQ ID NO: 1), high molecular weight adhesin 1 (HMW1A; SEQ ID NO: 2), putative periplasmic chelated iron binding proteins (SEQ ID NO: 3), IgA-specific serine endopeptidase (SEQ ID NO: 4), outer membrane protein P5 (OMP P5; SEQ ID NO: 5), galactose- 1 -phosphate uridylyltransferase (SEQ ID NO: 6), HMWA (SEQ ID NO: 7), phosphate ABC transporter phosphate-binding protein (SEQ ID NO: 8), putative adhesin B precursor FimA (SEQ ID NO: 9), high molecular weight adhesin 2 (HMW2A; SEQ ID NO: 10), outer membrane protein P5 precursor (SEQ ID NO: 11) and outer membrane protein PI (OMP PI; SEQ ID NO: 12).
  • OMP P2
  • the methods of the invention include detecting at least one biomarker, at least two biomarkers, at least three biomarkers, at least four biomarkers, at least five biomarkers or six or more biomarkers of the protein profile of a pathogenic bacteria.
  • Detection of the protein biomarkers includes detecting full length or fragments of the protein biomarkers, including immunogenic or biologically active fragments.
  • the methods of the invention include detecting at least OMP P2 and OMP 5 to generate a protein profile of NTHI bacteria.
  • the invention also provides biologically active or immunologically active variants of the amino acid sequences of the present invention; and "substantial equivalents" thereof (e.g., with at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, 86%, 87%, 88%, 89%, at least about 90%, 91%, 92%, 93%, 94%, typically at least about 95%, 96%, 97%, more typically at least about 98%, or most typically at least about 99% amino acid identity) that retain biological and/or immunogenic activity.
  • substantially equivalents e.g., with at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, 86%, 87%, 88%, 89%, at least about 90%, 91%, 92%, 93%, 94%, typically at least about 95%, 96%, 97%, more typically at least about 98%, or most typically at least about 99% amino acid identity
  • Polypeptides encoded by allelic variants may have a similar, increased, or decreased activity compared to polypeptides encoded by the native polynucleotides.
  • the present invention further provides isolated polypeptides or peptides encoded by the nucleic acid fragments or by degenerate variants of the nucleic acid fragments.
  • degenerate variant refers to nucleotide fragments which differ from a native nucleic acid fragment (e.g., an ORF) by nucleotide sequence but, due to the degeneracy of the genetic code, encode an identical polypeptide sequence.
  • Preferred nucleic acid fragments are the ORFs that encode proteins.
  • the invention also provides for polypeptides with one or more conservative amino acid substitutions that do not affect the biological and/or immunogenic activity of the polypeptide.
  • the polypeptides are contemplated to have conservative amino acids substitutions which may or may not alter biological activity.
  • conservative amino acid substitution refers to a substitution of a native amino acid residue with a nonnative residue, including naturally occurring and nonnaturally occurring amino acids, such that there is little or no effect on the polarity or charge of the amino acid residue at that position. For example, a conservative substitution results from the replacement of a non-polar residue in a polypeptide with any other non-polar residue.
  • any native residue in the polypeptide may also be substituted with alanine, according to the methods of "alanine scanning mutagenesis".
  • Naturally occurring amino acids are characterized based on their side chains as follows: basic: arginine, lysine, histidine; acidic: glutamic acid, aspartic acid;
  • uncharged polar glutamine, asparagine, serine, threonine, tyrosine; and non-polar:
  • polypeptides may be encoded by nucleotide sequences that are substantially equivalent to the polynucleotides encoding the polypeptide biomarkers.
  • Polynucleotides according to the invention can have, e.g., at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically at least 90%, 91%, 92%, 93%, or 94% and even more typically at least 95%, 96%, 97%, 98% or 99% sequence identity to the native polynucleotide sequences.
  • nucleic acid sequence fragments that hybridize under stringent conditions to the nucleotide sequences encoding the polypeptide biomarkers or compliments thereof, which fragment is greater than about 5 nucleotides, preferably 7 nucleotides, more preferably greater than 9 nucleotides and most preferably greater than 17 nucleotides. Fragments of, e.g., 15, 17, or 20 nucleotides or more that are selective for (i.e., specifically hybridize to any one of the polynucleotides of the invention) are contemplated.
  • Probes capable of specifically hybridizing to a polynucleotide can differentiate polynucleotide sequences of the invention from other polynucleotide sequences in the same family of genes or can differentiate genes from other bacterial genes, and are preferably based on unique nucleotide sequences.
  • stringent is used to refer to conditions that are commonly understood in the art as stringent.
  • Hybridization stringency is principally determined by temperature, ionic strength, and the concentration of denaturing agents such as formamide.
  • Examples of stringent conditions for hybridization and washing are 0.015 M sodium chloride, 0.0015M sodium citrate at 65-68°C or 0.015 M sodium chloride, 0.0015M sodium citrate, and 50% formamide at 42 °C See Sambrook et al., Molecular Cloning: A Laboratory Manual, 2.sup.nd Ed., Cold Spring Harbor Laboratory, (Cold Spring Harbor, N.Y. 1989).
  • More stringent conditions may also be used, however, the rate of hybridization will be affected.
  • additional exemplary stringent hybridization conditions include washing in 6x.SSC 0.05% sodium pyrophosphate at 37 °C (for 14-base oligos), 48 °C (for 17-base oligos), 55 °C (for 20-base oligos), and 60 °C. (for 23-base oligos).
  • agents may be included in the hybridization and washing buffers for the purpose of reducing non-specific and/or background hybridization.
  • agents include 0.1% bovine serum albumin, 0.1% polyvinyl-pyrrolidone, 0.1% sodium pyrophosphate, 0.1% sodium dodecylsulfate, NaDodSO.sub.4, (SDS), ficoll, Denhardt's solution, sonicated salmon sperm DNA (or other non-complementary DNA), and dextran sulfate, although other suitable agents can also be used.
  • concentration and types of these additives can be changed without substantially affecting the stringency of the hybridization conditions.
  • Hybridization experiments are usually carried out at pH 6.8-7.4, however, at typical ionic strength conditions, the rate of hybridization is nearly independent of pH. See Anderson et al., Nucleic Acid Hybridisation: A Practical Approach, Ch. 4, IRL Press Limited (Oxford, England). Hybridization conditions can be adjusted by one skilled in the art in order to accommodate these variables and allow DNAs of different sequence relatedness to form hybrids.
  • sequences falling within the scope of the present invention are not limited to these specific sequences, but also include allelic and species variations thereof.
  • Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package, including GAP (Devereux et al., Nucl. Acid. Res., 12:387,-1984; Genetics Computer Group, University of Wisconsin, Madison, Wis.), BLASTP, BLASTN, and FASTA (Altschul et al., J. Mol. Biol., 215: 403- 410, 1990).
  • the BLASTX program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul et al.
  • the well known Smith Waterman algorithm may also be used to determine identity.
  • the methods of the invention involve generating a protein profile of secretion samples obtained from the upper respiratory tract of a subject and generating protein profiles of pathogenic bacteria biofilm supernatants.
  • the known pathogenic bacteria biofilm protein profiles may be used as reference protein profiles for use in the methods of the invention.
  • Separation of protein of interest from the other members of the protein profile may be accomplished by any number of techniques, such as sucrose gradient centrifugation, aqueous or organic partitioning (e.g., two-phase partitioning), non-denaturing gel
  • electrophoresis isoelectric focusing gel electrophoresis, capillary electrophoresis, isotachyphoresis, mass spectroscopy, chromatography (e.g., HPLC), polyacrylamide gel electrophoresis (PAGE, such as SDS-PAGE), gel permeation, ion-exchange spin columns, and the like.
  • SELDI polyacrylamide gel electrophoresis
  • SELDI or other rapid analysis techniques, may be used for monitoring the purification process.
  • all potential biomarkers may be characterized by SDS PAGE and mass spectrometry and identified by peptide mapping and/or amino acid sequence analysis.
  • the protein biomarkers may be separated by size or buoyant density gradient separation method, such as a discontinuous sucrose gradient, that separates the component polypeptides of the sample by the sizes of the complexes in which they participate.
  • Sucrose gradients for the separation of proteins are well known, and may be modified as needed. Such modifications may include the use of a continuous, rather than discontinuous gradient, and different gradient conditions (for instance, different sucrose concentrations or different buffers).
  • the length of the gradient can also be varied, with longer gradients expected to give better overall separation of proteins and protein complexes, and to provide a larger number of fractions that are then each individually analyzed using a denaturing system.
  • the individual protein biomarkers may be separated by electrophoresis based upon size (e.g., by SDS-PAGE or sizing gel).
  • Other separation techniques may include aqueous two-phase partitioning and non-denaturing agarose gel electrophoresis separation.
  • separation employs denaturing system such as an isoelectric focusing (IEF) gel, capillary electrophoresis, or isotachyphoresis.
  • IEF isoelectric focusing
  • capillary electrophoresis capillary electrophoresis
  • isotachyphoresis e.g., Wilkins et al., Proteome Research: New Frontiers in Functional Genomics, Springer- Verlag, Berlin, 1997.
  • Proteins can be visualized on such gels using any of various stains known in the art (e.g., Trypan Blue or SyproRuby dye).
  • Traditional buffering systems can also be used for separating proteins in the component fractionations of the described systems.
  • the temperature, voltage, and amperage at which individual gels are run also can be modified, as can the speed and duration of gradient equilibration and centrifugation..
  • HPLC high pressure liquid chromatography
  • SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
  • a variety of methods may be used to generate the protein profile such as certain Matrix Assisted Laser Desorption Ionization (MALDI) Mass Spectrometry technology, Surface Enhanced Laser Desorption/Ionization (SELDI) and Protein Chip Mass
  • the methods may include steps for analyzing the protein profile.
  • analysis of the protein profile comprises a statistical analysis and other data manipulation techniques (e.g., signal processing, removal of noise).
  • techniques for analysis comprise computer statistical and data processing software.
  • analysis of the protein profile may comprise a determination of at least one of the molecular weight (mass), net charge, and or amount of the proteins in the sample.
  • the method may also comprise the step of comparing the protein profile for the subject's sample to a reference protein profile.
  • a reference protein profile may be from a healthy control subject who does not exhibit symptoms of the disease of interest (i.e., a negative control).
  • the reference profile may be from a subject who has a disease of interest (i.e., a positive control). Also, the sample protein profile ma" be compared to a reference protein profile isolated from the same subject, but at a different point in time (e.g., to monitor progression or remission of the disease). In yet other embodiments, the sample protein profile may be compared to a plurality of a reference protein profiles, as for example, reference profiles generated as diagnostic of a particular disease or disease subtype. In this way, it may be possible to determine whether the sample protein profile matches a particular protein or proteins of interest that are typical of any one disease or disease subtype.
  • kits for carrying out the methods and immunoassays of the invention comprise devices for obtaining the secretion sample from the sterile compartments within the upper respiratory tract of the subject.
  • the kits may also comprise antibodies that specifically bind the protein biomarkers of interest and components for immunoassays to detect the protein biomarkers using these antibodies.
  • the kits may comprise substrates presenting antibodies specific for the protein biomarkers of interest.
  • the kits may comprise instructions for carrying out the any of the methods or immunoassays of the invention.
  • secretions from the upper respiratory tract may be obtained using sterile swabs or gauze.
  • the secretion sample may be collected using nasal washing methods.
  • the secretion sample may be collected using a suction tube attached to an electric pump and a catheter inserted into the nasopharynx of the subject.
  • the device for obtaining the secretion sample is a modified balloon catheter Seldinger technique that allows for collection of secretions from the sterile compartments within the upper respiratory tract of the subject.
  • the balloon catheter may have a substrate presenting antibodies specific for the protein biomarkers of interest threaded into the catheter.
  • a modified distal chip brochoesophagoscope or transnasal esophagoscope may be used in which a substrate presenting antibodies specific for the protein biomarkers of interest is threaded into the suction port of the device.
  • the invention provides for an immunoassay for detecting at least one biomarker that is specific for a biofilm protein profile for a pathogenic bacteria. For example, antibodies specific for two or more biomarkers within the protein profile are presented or absorbed to a solid substrate, and the secretion sample obtained from the upper airway of the respiratory tract of a subject are contacted with the solid substrate and binding of the antibody to the substrate is detected.
  • any type of immunoassay system known in the art may be used to detect the biomarkers of the protein profiles.
  • Exemplary methods include, but not limited to:
  • radioimmunoassays radioimmunoassays, ELISA assays, sandwich assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, fluorescent
  • the immunoassays may be a sandwich assay in which the target analyte (biomarker of interest) is "sandwiched" between a labeled antibody and an antibody immobilized on the solid substrate. The immunoassay is read by observing the presence and amount of antigen-labeled antibody complex bound to the immobilized antibody.
  • Another immunoassay may also be a "competition" type
  • immunoassay wherein an antibody immobilized on a solid surface is contacted with a sample (e.g., secretions from the upper respiratory tract) containing both an unknown quantity of antigen analyte (biomarker of interest) and with labeled antigen of the same type. The amount of labeled antigen bound on the solid substrate is then determined to provide an indirect measure of the amount of antigen analyte (biomarker of interest) in the sample.
  • a sample e.g., secretions from the upper respiratory tract
  • a sample e.g., secretions from the upper respiratory tract
  • the amount of labeled antigen bound on the solid substrate is then determined to provide an indirect measure of the amount of antigen analyte (biomarker of interest) in the sample.
  • Such immunoassays are readily performed in a "dipstick” or other test device format (e.g., a flow- through or migratory dipstick or other test device design) for convenient use. For example, numerous types of dipstick immuno
  • the immune assays may be carried out on sheets, e.g. strips or sheet s of nitrocellulose or polyvinylidene difloride (PVDH) or other membranes, dipstick, wells e.g. 96- well plastic plates, or in tubes.
  • sheets e.g. strips or sheet s of nitrocellulose or polyvinylidene difloride (PVDH) or other membranes, dipstick, wells e.g. 96- well plastic plates, or in tubes.
  • PVDH polyvinylidene difloride
  • a device used in the methods and immunoassays of the invention can, for example, provide a color indication when the biomarker of interest is within the secretion sample from the upper respiratory tract of a subject.
  • the device could be used in a clinical setting to quickly determine if a subject has a pathological bacteria or a bacterial infection in the upper respiratory tract.
  • the methods and immunoassays of the present invention may be used in combination with a densitometer or generally a device for measuring light intensity, transmittance, reflection or refraction, or for measuring the wavelength of light as a measure of assay result.
  • the densitometer or other device can provide rapid measurement of the optical density of the substrate within the device that have been contacted with the secretions sample. In one embodiment, a change in color, density, or other parameter can be read by the naked eye.
  • the invention also may be carried out using a lateral-flow immunoassay which contains a device within the assay to extract the sample for analysis, and antibodies specific for the proteins within the protein profile of a pathogenic bacteria of interest.
  • the invention also provides for a immunoassay device, for example, such as those described in US Patent Nos. 5,415,994 and 5,763,262, which comprise a protein profile identified for a particular pathogenic bacteria using any of the method of the invention.
  • the invention provides for colorimetric immunoassays that allow for visual detection of the biomarkers of interest within the secretion sample. Visual detection allows for a rapid result which can be incorporated into a treatment plan for the infection.
  • a reference or standard protein profile may be used in the methods of the invention to compare the sample protein profile generated by the methods, immunoassays or kits of the invention.
  • the reference or standard protein profile provides the concentration of a biomarker known to be present in the biofilm secretion of a pathogenic bacteria within the upper respiratory tract during an infection.
  • a "calibrator” refers to immunoassays that detect known amounts of biomarkers of interest to generate a calibration curve to quantify the concentration of the biomarker in an unknown biological fluid.
  • standard refers to immunoassays that measure biomarkers of interest from biological fluids known to be collected from a subject having a bacterial infection of the upper respiratory tract in a suitable quantitative form to control the quality of reagents contained in an immunoassay kit of the present invention.
  • Other aspects and advantages of the present invention will be understood upon consideration of the following illustrative examples.
  • NTHI Nontypeable H. influenzae
  • the proteins isolated from NTHI biofilm supernatants were analyzed by nano- liquid chromatography/tandem mass spectrometry (LC-MS/MS).
  • the molecular weights of the identified proteins were compared to the molecular weights of the known protein profile for the NTHI strain 86-028NP ((Bakaletz et al. Infection and Immunity, 56(2): 331-335, 1988), and the identified proteins were scored based on their association to the 86-028NP protein profile using Mascot (Matrix Science, Boston MA) according to the manufacturer's instructions.
  • the results of this comparison are set out in Table 2 below.
  • OMPs outer membrane proteins
  • HMW1/HMW2 high molecular weight adhesins 1 and 2
  • OMP P5 high molecular weight adhesins 1 and 2
  • OMP P2 high molecular weight adhesins 1 and 2
  • IgA-protease IgA-protease
  • Outer membrane protein PI 21 49.7 gi ⁇ 9716607 13 One example of a signature protein profile of pathogenic NTHI biofilm is OMP P5, OMP P2, HMW1 and HMW2. Therefore, detection of these protein biomarkers in a secretion sample obtained from the upper respiratory tract is indicative of NTHI infection. Precise diagnosis of pathogenic bacterial infection, such as NTHI infection, in patients with upper airway infection will facilitate the selection of appropriate therapy and promote judicious prescription of antibiotics in order to achieve an early recovery in patients and to reduce the emergence of antibiotic-resistant infections in the community.
  • Example 1 The methods described in Example 1 are carried out with the supernatants from biofilms of other pathogenic bacteria species such as Streptococcus pneumonia, Moraxella catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
  • pathogenic bacteria species such as Streptococcus pneumonia, Moraxella catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
  • NTHI influenzae
  • NTHI strains 86-028NP, 1128MEE, 1714, 1748, 1885MEE and 2019 were cultured in eight-well chamber slides for 10 days and the resulting supernatants were collected at 24 hours intervals.
  • the proteins in the supernatants collected from NTHI biofilm cultures were separated by SDS-PAGE and silver staining revealed a distinct protein profile maintained over time.
  • Figure 3 depicts a Western blot using chinchilla anti-OMP P2 or anti-OMP P5 antibodies, which demonstrates that OMP P2 and OMP P5 are present in high levels in the biofilms of all NTHI strains tested.
  • the proteins isolated from NTHI biofilm supernatants were analyzed by nano- liquid chromatography/tandem mass spectrometry (LC-MS/MS).
  • the molecular weights of the identified proteins were compared to the molecular weights of the known protein profile for the NTHI strain 86-028NP ((Bakaletz et al. Infection and Immunity, 56(2): 331-335, 1988), and the identified proteins were scored based on their association to the 86-028NP protein profile using Mascot (Matrix Science, Boston MA) according to the manufacturer's instructions.
  • the results of this comparison are set out in Table 3 below.
  • the isolated proteins were also purified using cationic and gel chromatography .
  • the purified OMP P2 and OMP P5 protein will be used to generate monoclonal antibodies for use in the methods, immunoassays and devices of the invention. It is critical that the antibodies used in the methods, immunoassays and devices of the invention be highly specific.
  • the currently available chinchilla polyclonal antibodies do not exhibit the specificity necessary for carrying out the methods of the invention.
  • a mouse is immunized intraperitoneally with the purified OMP P2 protein or purified OMP P5 protein.
  • the mouse is sacrificed and spleen cells are fused with murine myeloma cells using methods standard in the art.
  • hybridoma technology is described in Kohler et al., Nature 256: 495
  • the human B-cell hybridoma technique is described in Kozbor et al., Immunol. Today 4, 72 (1983)
  • the EBV- hybridoma technique to produce human monoclonal antibodies is described in Cole et al. Monoclonal Antibodies in Cancer Therapy (1985) Allen R. Bliss, Inc., pages 77-96
  • methods of screening combinatorial antibody libraries is described in Huse et al., Science 246, 1275 (1989).
  • the fused cells are cloned in a 96-well plate for single colony selection. Seven to ten days after fusion, culture supernatants from each well with colonies are assayed for the presence of anti-OMP P2 or anti-OMP P5 antibodies. Two to four weeks after cloning, supernatants from single cell colonies are screen for the presence of anti-OMP P2 or anti- OMP P5 antibodies again. Wells with positive reactions are further expanded into larger wells and eventually expanded into flasks to harvest more supernatant for further testing.
  • Hybridoma cells from the positive clones are injected into pristine mice for production of ascites.
  • the monoclonal antibodies are purified from the ascites, and the specificity of the purified monoclonal antibodies is tested using standard assays known in the art.
  • Anti-OMP P2 and OPM P5 monoclonal antibodies are used to in order to determine the protein profile of a human patient suffering from sinusitis.
  • Secretion samples are obtained from the upper respiratory tract of the patients. These samples are analyzed as described in Example 1 for the presence of at least OMP P5, OMP P2, HMW1 or HMW2. The protein profile of the patients is compared with the reference protein profile generated from the supernatants of in vitro NTHI biofilms as described above
  • the sensitivity and specificity parameters for the use of anti-OMP P2 and anti- OPM P5 monoclonal antibodies, as described in Example 5, are determined against a gold- standard real-time PCR assay using hpd as a primer for the detection of non-typeable Haemophilus influenzae that has been shown to be 100% specific and sensitive for the detection of NTHI strains 86-028NP, 1128MEE, 1714, 1748, 1885MEE and 2019 and several clinical isolates of Moraxella catarrhalis.

Abstract

L'invention concerne une approche protéomique pour l'identification de profils protéiques bactériens spécifiques qui peuvent être utilisés dans le développement de méthodes de diagnostic d'une sinusite chronique bactérienne. L'invention concerne des procédés de détermination de la présence de bactéries pathogènes dans le tractus respiratoire supérieur d'un sujet à l'aide des profils protéiques des bactéries pathogènes. L'invention concerne également des méthodes de diagnostic d'une infection bactérienne du tractus respiratoire supérieur d'un sujet à l'aide de profils protéiques d'une bactérie pathogène. De plus, l'invention concerne des dispositifs, immunodosages et trousses pour l'identification de bactéries pathogènes dans le tractus respiratoire supérieur.
EP12726000.8A 2011-06-06 2012-06-05 Procédé de détection de diagnostic à base de protéomique d'une sinusite chronique Active EP2718722B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL12726000T PL2718722T3 (pl) 2011-06-06 2012-06-05 Oparty na proteomice diagnostyczny sposób wykrywania przewlekłego zapalenia zatok

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161493829P 2011-06-06 2011-06-06
PCT/US2012/040910 WO2012170422A1 (fr) 2011-06-06 2012-06-05 Procédé de détection de diagnostic à base de protéomique d'une sinusite chronique

Publications (2)

Publication Number Publication Date
EP2718722A1 true EP2718722A1 (fr) 2014-04-16
EP2718722B1 EP2718722B1 (fr) 2017-10-18

Family

ID=46208851

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12726000.8A Active EP2718722B1 (fr) 2011-06-06 2012-06-05 Procédé de détection de diagnostic à base de protéomique d'une sinusite chronique

Country Status (9)

Country Link
US (4) US9568472B2 (fr)
EP (1) EP2718722B1 (fr)
JP (2) JP6050337B2 (fr)
AU (1) AU2012268380C1 (fr)
CA (1) CA2838488C (fr)
DK (1) DK2718722T3 (fr)
ES (1) ES2649370T3 (fr)
PL (1) PL2718722T3 (fr)
WO (1) WO2012170422A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012254213A1 (en) * 2011-05-11 2013-11-28 Riesbeck Healthcare Sweden Ab Protein F - a novel Haemophilus influenzae adhesin with laminin and vitronectin binding properties
WO2012170422A1 (fr) * 2011-06-06 2012-12-13 Nationwide Children's Hospital, Inc. Procédé de détection de diagnostic à base de protéomique d'une sinusite chronique
AU2013215630B2 (en) * 2012-02-01 2016-05-26 Oklahoma Medical Research Foundation Human Streptococcus pneumoniae antibodies and uses therefor
JP2016529257A (ja) * 2013-08-16 2016-09-23 オハイオ ステート イノベーション ファウンデーション Ｄｎａメチル化を調節する組成物及び方法
US10921320B2 (en) 2015-03-30 2021-02-16 Entvantage Diagnostics, Inc. Devices and methods for diagnosis of sinusitis
SI3075862T1 (en) 2015-03-30 2018-02-28 Entvantage Diagnostics, Inc. Aids and tests for the diagnosis of sinusitis
US11650213B2 (en) 2015-03-30 2023-05-16 Entvantage Diagnostics, Inc. Devices and assays for diagnosis of viral and bacterial infections
WO2018183421A1 (fr) 2017-03-28 2018-10-04 Entvantage Diagnostics, Inc. Dispositifs et procédés de diagnostic de la sinusite

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0664065B2 (ja) * 1985-12-23 1994-08-22 日水製薬株式会社 菌体外膜保有菌の免疫学的測定法
US5763262A (en) 1986-09-18 1998-06-09 Quidel Corporation Immunodiagnostic device
KR910014706A (ko) 1990-01-10 1991-08-31 원본미기재 세척이 필요없는 개량된 이뮤노어세이(immunoassay)장치
US20020164354A1 (en) * 1998-09-30 2002-11-07 Barenkamp Stephen J. High molecular weight surface proteins of non-typeable haemphilus
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
ATE527059T1 (de) * 2004-03-18 2011-10-15 Nissui Pharm Co Ltd Methode zur herstellung einer analytischen vorrichtung und kit
AU2010204066B2 (en) * 2009-01-07 2015-03-19 Otsuka Pharmaceutical Co., Ltd. Method for detecting all Haemophilus influenzae
WO2010092176A2 (fr) * 2009-02-13 2010-08-19 Intercell Ag Antigènes haemophilus influenzae non typables
US20120276145A1 (en) * 2011-03-28 2012-11-01 House Research Institute Extracellular matrix proteins from haemophilus influenzae biofilms: targets for therapeutic or diagnostic use
WO2012170422A1 (fr) * 2011-06-06 2012-12-13 Nationwide Children's Hospital, Inc. Procédé de détection de diagnostic à base de protéomique d'une sinusite chronique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
L A Novotny ET AL: "Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae", Mucosal Immunology, vol. 4, no. 4, 16 February 2011 (2011-02-16), pages 456-467, XP55147134, ISSN: 1933-0219, DOI: 10.1038/mi.2011.6 *
See also references of WO2012170422A1 *

Also Published As

Publication number Publication date
CA2838488C (fr) 2020-06-30
ES2649370T3 (es) 2018-01-11
US10345300B2 (en) 2019-07-09
US20140314876A1 (en) 2014-10-23
JP2014523525A (ja) 2014-09-11
DK2718722T3 (en) 2018-01-15
WO2012170422A1 (fr) 2012-12-13
CA2838488A1 (fr) 2012-12-13
PL2718722T3 (pl) 2018-04-30
EP2718722B1 (fr) 2017-10-18
AU2012268380A1 (en) 2014-01-16
US9568472B2 (en) 2017-02-14
JP6050337B2 (ja) 2016-12-21
US10725040B2 (en) 2020-07-28
AU2012268380B2 (en) 2017-01-05
JP2016194532A (ja) 2016-11-17
US20190324037A1 (en) 2019-10-24
AU2012268380C1 (en) 2017-03-23
US10048261B2 (en) 2018-08-14
US20190004046A1 (en) 2019-01-03
US20170184589A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
US10725040B2 (en) Proteomics based diagnostic detection method for chronic sinusitis
JPWO2015025968A1 (ja) マイコプラズマ・ニューモニエの免疫学的検出法およびキット
WO2016092096A1 (fr) Anticorps anti-carbapénémases et leurs utilisations
EP3252472B1 (fr) Procédé et kit de détection immunologique pour mycoplasma pneumoniae
JP2022048268A (ja) マイコプラズマ・ニューモニエの免疫学的検出法及びキット
EP2619583B1 (fr) Méthode de diagnostic d'une méningite bactérienne
Wu et al. Diagnostic value of quantitative MP-IgG for Mycoplasma pneumoniae pneumonia in adults
WO2005114196A1 (fr) Procédé d'examen de cystite interstitiale
Tirone et al. Correlation of Levels of α–Defensins Determined by HPLC-ESI-MS in Bronchoalveolar Lavage Fluid With the Diagnosis of Pneumonia in Premature Neonates
Hotomi et al. An application of outer membrane protein p6-specific enzyme-linked immunosorbent assay for detection of Haemophilus influenzae in middle ear fluids and nasopharyngeal secretions
CN115136009A (zh) 用于呼吸道感染诊断的生物标志物
WO2020027617A1 (fr) Procédé de diagnostic du typhus des broussailles à l'aide d'une vésicule de membrane externe dérivée d'o. tsutsugamushi
TWI536017B (zh) Detection of hemolytic uremia by using serum fetuin A as a biomarker to detect streptococcus pneumoniae infection
US20130005836A1 (en) Composition and methods related to s100 a2
KR102515934B1 (ko) 비감염성 폐질환 진단을 위한 바이오마커로서 cd20의 용도
US9261504B1 (en) Method and kit for detection of hemolytic uremic syndrome and necrotizing pneumonia in children with pneumococcal disease using serum fetuin-A levels as a biomarker
CN108414765A (zh) 用G72蛋白质与SLC7A11mRNA作为生物标记来诊断与治疗阿兹海默氏症的方法
CN106526193B (zh) 蛋白质gp1ba/vwf用作检测2型糖尿病的分子标记的应用
KR20160073699A (ko) 폐렴환자 소변에서 발굴된 폐렴연쇄상구균 진단용 바이오마커
Castanhinha et al. 134 Serology and clinical parameters for diagnosis of Pseudomonas aeruginosa infection in children with cystic fibrosis
WO2010031127A1 (fr) Détection d'une infection à tréponèmes
KR20110040297A (ko) Ｍ. 투버쿨로시스 진단용 조성물 및 이를 이용한 진단방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131218

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: THE OTHER INVENTOR HAS AGREED TO WAIVE HIS ENTITLE

Inventor name: BAKALETZ, LAUREN, O.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DAS, SUBINOY

Inventor name: BAKALETZ, LAUREN, O.

17Q First examination report despatched

Effective date: 20141022

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101AFI20170202BHEP

Ipc: G01N 33/569 20060101ALI20170202BHEP

Ipc: C12Q 1/04 20060101ALI20170202BHEP

INTG Intention to grant announced

Effective date: 20170306

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

INTG Intention to grant announced

Effective date: 20170831

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 938407

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171115

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012038654

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2649370

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180111

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180109

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 938407

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171018

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180118

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180118

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180119

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180218

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012038654

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

26N No opposition filed

Effective date: 20180719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180605

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20200313

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20120605

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171018

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171018

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20200610

Year of fee payment: 9

Ref country code: IE

Payment date: 20200609

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20200512

Year of fee payment: 9

Ref country code: NL

Payment date: 20200615

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20200701

Year of fee payment: 9

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20210630

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20210701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210605

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210630

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210605

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230517

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230510

Year of fee payment: 12

Ref country code: DE

Payment date: 20230510

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230510

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20230517

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230504

Year of fee payment: 12

Ref country code: CH

Payment date: 20230702

Year of fee payment: 12